Evidence map›Paper›PMID 34426830›Full record

ArticleBJS open2021

Liver resection and ablation for squamous cell carcinoma liver metastases.

J Engstrand, L F Abreu de Carvalho, D Aghayan, A Balakrishnan, A Belli, B Björnsson, B V M Dasari, O Detry, M Di Martino, B Edwin and 29 more

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BJS open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 9 citations in OpenAlex.

  1. SEOM-GEMCAD-TTD clinical guidelines for anal cancer (2025).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Guideline
  2. Pooled it
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

39 authors at 20 institutions in 13 countries.

J EngstrandDivision of Surgery, Department of Clinical Sciences, Karolinska Institutet at Danderyd Hospital, Stockholm, Sweden.ORCID 0000-0003-1123-7022
L F Abreu de CarvalhoDepartment of Hepatopancreatobiliary Surgery and Liver Transplantation, Ghent University Hospital, Ghent, Belgium.
D AghayanThe Intervention Centre, Oslo University Hospital, Institute of Clinical Medicine, Medical Faculty, University of Oslo, Oslo, Norway.ORCID 0000-0001-7051-3512
A BalakrishnanDepartment of Surgery, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
A BelliDepartment of Abdominal Oncology, HPB Surgical Oncology Unit, National Cancer Institute, Fondazione G. Pascale-IRCCS, Naples, Italy.ORCID 0000-0002-6252-573X
B BjörnssonDepartment of Surgery in Linköping, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
B V M DasariDepartment of Hepatobiliary and Pancreatic Surgery, Queen Elizabeth Hospital, Birmingham, UK.
O DetryDepartment of Abdominal Surgery and Transplantation, CHU Liège, Liège, Belgium.ORCID 0000-0002-9436-6673
M Di MartinoHPB Unit, Department of General and Digestive Surgery, Hospital Universitario La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP), Universidad Autónoma de Madrid (UAM), Madrid, Spain.ORCID 0000-0001-6510-7210
B EdwinThe Intervention Centre, Oslo University Hospital, Institute of Clinical Medicine, Medical Faculty, University of Oslo, Oslo, Norway.
J ErdmannDepartment of Surgery, Cancer Centre Amsterdam, Amsterdam UMC, University of Amsterdam, the Netherlands.
R FristedtDepartment of Surgery, Skåne University Hospital, Lund University, Lund, Sweden.
G FusaiDepartment of HPB and Liver Transplant Surgery, Royal Free Hospital, NHS Foundation Trust, London, UK.
T Gimenez-MaurelDepartment of Surgery, Miguel Servet University Hospital, Zaragoza, Spain.
O HemmingssonDepartment of Surgical and Perioperative Sciences, Umeå University, Umeå, Sweden.ORCID 0000-0003-1732-168X
C Hidalgo SalinasDepartment of HPB and Liver Transplant Surgery, Royal Free Hospital, NHS Foundation Trust, London, UK.
B IsakssonDepartment of Surgical Sciences, Uppsala University, Uppsala, Sweden.
A IvaneczDepartment of Abdominal and General Surgery, University Medical Centre Maribor, Maribor, Slovenia.
F IzzoDepartment of Abdominal Oncology, HPB Surgical Oncology Unit, National Cancer Institute, Fondazione G. Pascale-IRCCS, Naples, Italy.
W T KnoefelDepartment of Surgery (A), Heinrich-Heine-University and University Hospital Düsseldorf, Düsseldorf, Germany.
P KronDepartment of Hepatobiliary Surgery, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
N Lehwald-TywuschikDepartment of Surgery (A), Heinrich-Heine-University and University Hospital Düsseldorf, Düsseldorf, Germany.
M LesurtelDepartment of Digestive Surgery and Liver Transplantation, Croix-Rousse University Hospital, Hospices Civils de Lyon, University of Lyon I, Lyon, France.ORCID 0000-0003-2397-4599
J P A LodgeDepartment of Hepatobiliary Surgery, Leeds Teaching Hospitals NHS Trust, Leeds, UK.ORCID 0000-0001-8771-4214
N Machairas3rd Department of Surgery, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece.ORCID 0000-0003-3239-3905
M V MarinoGeneral Surgery Department, Azienda Ospedaliera Ospedali Riuniti Villa Sofia-Cervello, Palermo (PA), Abano, Italy.ORCID 0000-0002-0466-4467
V MartinDepartment of Digestive Surgery and Liver Transplantation, Croix-Rousse University Hospital, Hospices Civils de Lyon, University of Lyon I, Lyon, France.
A PatersonDepartment of Surgery, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
J RystedtDepartment of Surgery, Skåne University Hospital, Lund University, Lund, Sweden.ORCID 0000-0002-8865-9963
P SandströmDepartment of Surgery in Linköping, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
A SerrabloDepartment of Surgery, Miguel Servet University Hospital, Zaragoza, Spain.
A K SiriwardenaHepatobiliary Surgery Unit, Manchester Royal Infirmary, Manchester, UK.
H TaflinDepartment of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, Sweden.
T M van GulikDepartment of Surgery, Cancer Centre Amsterdam, Amsterdam UMC, University of Amsterdam, the Netherlands.
S YaqubDepartment of Hepato-Pancreato-Biliary Surgery, Oslo University Hospital, Oslo, Norway.ORCID 0000-0002-5696-2319
I ÖzdenDepartment of General Surgery, Istanbul University School of Medicine, Istanbul, Turkey.
J M RamiaHospital General Universitario de Alicante. ISABIAL Alicante, Spain.ORCID 0000-0001-7734-9479
C SturessonDivision of Surgery, Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.ORCID 0000-0003-3451-2840
E-AHPBA Scientific and Research Committee
Oslo University Hospital · NOAmsterdam University Medical Centers · NLCambridge University Hospitals NHS Foundation Trust · GBDüsseldorf University Hospital · DEHospital Universitario Miguel Servet · ESIstituto Nazionale Tumori IRCCS "Fondazione G. Pascale" · ITLeeds Teaching Hospitals NHS Trust · GBLinköping University · SELund University · SERoyal Free London NHS Foundation Trust · GBUniversité Claude Bernard Lyon 1 · FRGhent University Hospital · BEHospital General Universitario de Alicante Doctor Balmis · ESHospital Universitario de La Princesa · ESIstanbul University · TRKarolinska Institutet · SEKarolinska University Hospital · SEManchester Royal Infirmary · GBNational and Kapodistrian University of Athens · GROspedale Vincenzo Cervello · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLimited evidence exists to guide the management of patients with liver metastases from squamous cell carcinoma (SCC). The aim of this retrospective multicentre cohort study was to describe patterns of disease recurrence after liver resection/ablation for SCC liver metastases and factors associated with recurrence-free survival (RFS) and overall survival (OS).

methodMembers of the European-African Hepato-Pancreato-Biliary Association were invited to include all consecutive patients undergoing liver resection/ablation for SCC liver metastases between 2002 and 2019. Patient, tumour and perioperative characteristics were analysed with regard to RFS and OS.

resultsAmong the 102 patients included from 24 European centres, 56 patients had anal cancer, and 46 patients had SCC from other origin. RFS in patients with anal cancer and non-anal cancer was 16 and 9 months, respectively (P = 0.134). A positive resection margin significantly influenced RFS for both anal cancer and non-anal cancer liver metastases (hazard ratio 6.82, 95 per cent c.i. 2.40 to 19.35, for the entire cohort). Median survival duration and 5-year OS rate among patients with anal cancer and non-anal cancer were 50 months and 45 per cent and 21 months and 25 per cent, respectively. For the entire cohort, only non-radical resection was associated with worse overall survival (hazard ratio 3.21, 95 per cent c.i. 1.24 to 8.30).

conclusionLiver resection/ablation of liver metastases from SCC can result in long-term survival. Survival was superior in treated patients with liver metastases from anal versus non-anal cancer. A negative resection margin is paramount for acceptable outcome.

Indexed as

Carcinoma, Squamous CellLiver NeoplasmsCohort StudiesHumansNeoplasm Recurrence, LocalRetrospective Studies

Identifiers

PMID34426830
PMCPMC8382975
OpenAlexW3193652529

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.